FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2227499032> ?p ?o ?g. }

• W2227499032 abstract "15093 Background: EC is a highly lethal disease with 5 year survival less than 15%. Surgery offers a chance for cure in early disease. Still, fewer than 20% of pts treated with surgery alone are alive at 5 years. Neoadjuvant chemoradiation offers the theoretical advantage of increasing R0 resections and reducing early local and distal metastases which may translate into improved survival. Several clinical trials have resulted in pathologic complete response (pCR) rates of 20–30%. Methods: Newly diagnosed pts with EC Stage 2A (T3) to 4 received weekly Docetaxel (D)25–30mg/m2 and Cisplatin (C)25–30mg/m2.for 6–8 weeks concurrently with radiation, 5040 cGy in 28 fractions. Cetuximab (E) 200mg/m2 was added after it became accepted treatment in head and neck cancers. Pts were scheduled 4 - 6 weeks later for surgery followed by the same chemotherapy for total of 16 weeks of treatment. Pts were assessed for time to progression, overall survival and toxicities. Results: Fifteen pts treated in 2005–6 underwent IRB approved evaluation; 11 male and 4 female, median age of 62(range 44–78) . Four had squamous cell (SCC) and 11 adenocarcinomas. Nine pts had Stage II, 4 pts stage III and 2 pts stage IV disease. Seven pts underwent surgery, all R0 resections. Four of them had pCR, one pPR (downstaged from T3 to T1) and two pts had stable disease. An additional 3 pts had radiological and endoscopic proven CR (medically not surgical candidates) for an objective response (CR+PR) in 8 out of 15 pts (3 SCC and 5 adenoca). Five out of 9 receiving DC had an objective response while 3 of 6 receiving DCE responded. Five pts progressed prior to surgery. Grade 3/4 neutropenia occurred in 2, nausea in 3, and 1 pt experienced Grade 3 dehydration. Four patients required dose reductions by 20%. Six patients had one cycle and 2 had 3 cycles delayed by one week each. Conclusions: Neoadjuvant chemoradiation treatment with weekly Docetaxel and Cisplatin ± Cetuximab is tolerable with high rate of CRs. There was no observed difference in response with the addition of cetuximab. A Phase III study is suggested. No significant financial relationships to disclose." @default.
• W2227499032 created "2016-06-24" @default.
• W2227499032 creator A5008907100 @default.
• W2227499032 creator A5010862775 @default.
• W2227499032 creator A5011200145 @default.
• W2227499032 creator A5024388002 @default.
• W2227499032 creator A5044082128 @default.
• W2227499032 creator A5059464864 @default.
• W2227499032 creator A5071552913 @default.
• W2227499032 creator A5080479995 @default.
• W2227499032 creator A5089483620 @default.
• W2227499032 date "2007-06-20" @default.
• W2227499032 modified "2023-09-24" @default.
• W2227499032 title "High complete response (CR) rate in patients (pts) with esophageal carcinoma (EC) undergoing neoadjuvant combination of docetaxel and cisplatin (DC) ± cetuximab(DCE) chemoradiation therapy—a retrospective analysis" @default.
• W2227499032 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.15093" @default.
• W2227499032 hasPublicationYear "2007" @default.
• W2227499032 type Work @default.
• W2227499032 sameAs 2227499032 @default.
• W2227499032 citedByCount "0" @default.
• W2227499032 crossrefType "journal-article" @default.
• W2227499032 hasAuthorship W2227499032A5008907100 @default.
• W2227499032 hasAuthorship W2227499032A5010862775 @default.
• W2227499032 hasAuthorship W2227499032A5011200145 @default.
• W2227499032 hasAuthorship W2227499032A5024388002 @default.
• W2227499032 hasAuthorship W2227499032A5044082128 @default.
• W2227499032 hasAuthorship W2227499032A5059464864 @default.
• W2227499032 hasAuthorship W2227499032A5071552913 @default.
• W2227499032 hasAuthorship W2227499032A5080479995 @default.
• W2227499032 hasAuthorship W2227499032A5089483620 @default.
• W2227499032 hasConcept C121608353 @default.
• W2227499032 hasConcept C126322002 @default.
• W2227499032 hasConcept C141071460 @default.
• W2227499032 hasConcept C143998085 @default.
• W2227499032 hasConcept C167135981 @default.
• W2227499032 hasConcept C2776694085 @default.
• W2227499032 hasConcept C2778239845 @default.
• W2227499032 hasConcept C2778292576 @default.
• W2227499032 hasConcept C2779998722 @default.
• W2227499032 hasConcept C2781190966 @default.
• W2227499032 hasConcept C3019096185 @default.
• W2227499032 hasConcept C509974204 @default.
• W2227499032 hasConcept C526805850 @default.
• W2227499032 hasConcept C530470458 @default.
• W2227499032 hasConcept C71924100 @default.
• W2227499032 hasConceptScore W2227499032C121608353 @default.
• W2227499032 hasConceptScore W2227499032C126322002 @default.
• W2227499032 hasConceptScore W2227499032C141071460 @default.
• W2227499032 hasConceptScore W2227499032C143998085 @default.
• W2227499032 hasConceptScore W2227499032C167135981 @default.
• W2227499032 hasConceptScore W2227499032C2776694085 @default.
• W2227499032 hasConceptScore W2227499032C2778239845 @default.
• W2227499032 hasConceptScore W2227499032C2778292576 @default.
• W2227499032 hasConceptScore W2227499032C2779998722 @default.
• W2227499032 hasConceptScore W2227499032C2781190966 @default.
• W2227499032 hasConceptScore W2227499032C3019096185 @default.
• W2227499032 hasConceptScore W2227499032C509974204 @default.
• W2227499032 hasConceptScore W2227499032C526805850 @default.
• W2227499032 hasConceptScore W2227499032C530470458 @default.
• W2227499032 hasConceptScore W2227499032C71924100 @default.
• W2227499032 hasLocation W22274990321 @default.
• W2227499032 hasOpenAccess W2227499032 @default.
• W2227499032 hasPrimaryLocation W22274990321 @default.
• W2227499032 hasRelatedWork W2010389831 @default.
• W2227499032 hasRelatedWork W2015271374 @default.
• W2227499032 hasRelatedWork W2029866643 @default.
• W2227499032 hasRelatedWork W2034905626 @default.
• W2227499032 hasRelatedWork W2249146942 @default.
• W2227499032 hasRelatedWork W2356838307 @default.
• W2227499032 hasRelatedWork W2588327209 @default.
• W2227499032 hasRelatedWork W2591479921 @default.
• W2227499032 hasRelatedWork W2954897945 @default.
• W2227499032 hasRelatedWork W4295817748 @default.
• W2227499032 isParatext "false" @default.
• W2227499032 isRetracted "false" @default.
• W2227499032 magId "2227499032" @default.
• W2227499032 workType "article" @default.